MBIO - LSD Microdosing For PMS? After Confirming Antidepressant Effects Clinical Trials Will Assess If It Addresses Mood Issues | Benzinga
The Australian-based biopharma company MindBio Therapeutics Corp. (CSE:MBIO) obtained regulatory approval for a series of clinical trials in women's health using its proprietary LSD drug, MB22001. The company said it is the only one in the world with regulatory approvals of the take-home use of this type of scheduled drug in clinical trials.
MB22001 is designed for take-home self-administration by patients. The company’s thesis is that it can be used acutely during specific periods of the menstrual cycle, with targeted dosing to treat negative mood symptoms. This thesis is based on three main facts a) The acute dose day mood-elevating effects of MB22001 have been demonstrated in MindBio's Phase 1 trials b) MindBio's Phase 2a open-label trial in depressed patients show long-term improvements in mood and c) reports in ...